Boston Scientific Investor Day Summary Company Overview - **Company**: Boston Scientific - **Industry**: Medical Devices - **Event**: Investor Day Key Points and Arguments Company Vision and Culture - Boston Scientific aims to be a leader in the medical device industry, focusing on "advancing science for life" as a core mission [6][7][21] - The company emphasizes the importance of employee engagement and culture as key differentiators in its success [7][23] Financial Performance and Growth Projections - The company projects **14% to 15% organic growth** for 2025, following a **16% organic growth** in 2024 [8][11] - Anticipated **18% to 19% EPS growth** for the current year [9] - Boston Scientific aims for **10%+ organic growth** over the next three years, outpacing the market CAGR of **9%** [11][12] - The company has a history of meeting or exceeding Investor Day targets, instilling confidence in shareholders [10][11] Business Units and Market Performance - Boston Scientific operates across **eight business units**, with notable growth in **Cardiovascular** and **MedSurg** sectors [9][10] - The company has seen impressive growth in the **Asia Pacific** region, particularly in **China**, which is projected to generate over **$1 billion** in revenue by 2025 [24][28] - The international market, including EMEA and Latin America, represents about **35%** of revenue in 2025, with plans to increase this percentage [25] Innovation and R&D - Boston Scientific is committed to a robust **innovation ecosystem**, integrating R&D, venture capital, and M&A to drive growth [17][18] - The company has made significant investments in **AI and automation** within its manufacturing processes to enhance efficiency [27] - A focus on **category leadership** in specific medical fields, such as neuromodulation and urology, is central to its strategy [12][33] China Market Strategy - Boston Scientific has doubled its revenue and employee base in China over the last five years, significantly outpacing competitors [28][29] - The company has adopted a **localization strategy**, investing in local innovative companies to enhance its portfolio [30][31] - Boston Scientific has successfully navigated the **Volume-Based Purchasing (VBP)** environment, allowing for expanded access to the healthcare system despite price pressures [32] MedSurg and Urology Business Insights - The MedSurg segment, including neuromodulation, urology, and endoscopy, is projected to grow above market rates, driven by a strong pipeline and category leadership [33][48] - The urology market is estimated at **$7 billion**, with expectations for high single-digit growth fueled by extensive product offerings and global expansion [48][49] - Innovations in urology include the **stone-smart ecosystem** aimed at improving surgical outcomes and reducing postoperative infections [52][53] Neuromodulation and Pain Management - The neuromodulation segment focuses on chronic pain and movement disorders, with a goal of high single-digit growth driven by innovative therapies [37][45] - Key growth drivers include the **Intracept therapy** for chronic low back pain and advancements in **Deep Brain Stimulation (DBS)** technologies [40][43] Conclusion - Boston Scientific is positioned for continued growth through a combination of strong financial performance, innovative product development, and strategic market expansion, particularly in underpenetrated international markets [21][24][25][32]